"Palisade Bio's PALI-2108 Shows Promise, Stock Surges 150%"
Palisade Bio presented positive preclinical data of its lead program PALI-2108 at the 2024 Crohn’s & Colitis Congress, demonstrating its safety, local activity, and low systemic exposure for the treatment of moderate-to-severe ulcerative colitis. The orally delivered and colon-activated PALI-2108 is advancing toward a Phase 1 clinical study expected to commence in 2024, with promising outcomes including colon-specific distribution, dose-dependent efficacy in a mouse UC model, and no systemic toxicity in dogs, offering potential for revolutionizing UC treatment.